Related Experiment Video
Updated: May 19, 2026

Disruption of the Blood-Spinal Cord Barrier Using Low-Intensity Focused Ultrasound in a Rat Model
Published on: March 10, 2023
Antifibrinolytic agents reduce blood loss during pediatric vertebral column resection procedures
Peter O Newton1, Tracey P Bastrom, John B Emans
1Rady Children's Hospital, San Diego, CA, USA. pnewton@rchsd.org
Insights
Antifibrinolytic (AF) agents like tranexamic acid (TXA) significantly reduce blood loss during pediatric vertebral column resection (VCR). TXA demonstrated a notable decrease in estimated blood loss (EBL) compared to no AF use.
Area of Science:
- Pediatric Orthopedics
- Surgical Hemorrhage Control
- Pharmacology
Background:
- Vertebral column resection (VCR) in pediatric patients can lead to significant intraoperative blood loss.
- Effective strategies to mitigate blood loss during VCR are crucial for patient safety and outcomes.
Purpose of the Study:
- To evaluate the impact of intraoperative antifibrinolytic (AF) agents on blood loss during VCR procedures in pediatric patients.
- To compare the efficacy of different AF agents, including tranexamic acid (TXA), aminocaproic acid, and aprotinin, in reducing blood loss.
Main Methods:
- A retrospective multicenter review of 147 pediatric patients (<21 years) undergoing VCR for spinal deformity correction.
- Estimated blood loss (EBL) was calculated as a percentage of blood volume (%BV) and normalized per vertebral level excised (%BV/level).
- Analysis of covariance was used to compare EBL between groups receiving no AF, TXA, or aprotinin, controlling for deformity magnitude.
Main Results:
- The overall normalized EBL was 41% ± 39%, with significant variability.
- Patients receiving TXA (30% ± 34%) or aprotinin (32% ± 24%) had significantly lower normalized EBL compared to those receiving no AF (52% ± 37%).
- The efficacy of AF agents varied across participating centers.
Conclusions:
- Intraoperative antifibrinolytic agents, particularly TXA, can significantly reduce blood loss during pediatric VCR.
- While aprotinin also showed efficacy, it has since been withdrawn from the market.
- TXA offers a viable option for managing blood loss in these complex spinal surgeries, though site-specific effects warrant consideration.
Study Design:
Retrospective multicenter review.
Objective:
To evaluate the effect of intraoperative antifibrinolytic (AF) agents on blood loss associated with vertebral column resection (VCR) procedures for pediatric patients.
Summary Of Background Data:
VCR procedures may be associated with substantial blood loss.
Methods:
A multicenter review of 147 patients (aged <21 yr) who underwent VCR as part of their spinal deformity correction was conducted. Estimated blood loss (EBL) was calculated as percentage of blood volume (BV) (EBL/BV × 100), which was normalized on the basis of the number of vertebral levels removed (%BV/level). The use of AF agents was noted (tranexamic acid [TXA], aminocaproic acid, aprotinin, none) and based on surgeons' choice. EBL was compared using analysis of covariance (controlling for deformity magnitude) (P < 0.05).
Results:
Average preoperative major deformity (kyphosis or scoliosis) was 97° ± 31°. The average number of levels excised was 1.6 (range, 1-5). Total EBL averaged 1317 mL (range, 50-6026 mL). Eleven patients were excluded: 7 with incomplete data and 4 who received aminocaproic acid (too few to compare). This resulted in 136 cases; 64 with no AF, 42 received TXA, and 30 received aprotinin. Overall %BV/level EBL was 41% ± 39% (range, 6%-162%) and was significantly higher in the no-AF group (52% ± 37%) than the TXA (30% ± 34%; P < 0.01) and aprotinin (32% ± 24%; P < 0.05) groups. The effect of the AFs varied by site.
Conclusion:
EBL associated with VCR was highly variable and in many cases exceeded the patient's BV. AF agents were not routinely used and we had insufficient data to assess the efficacy of aminocaproic acid. Both aprotinin and TXA resulted in less EBL than when no AF was used; however, the effect of the reduction varied by site. Aprotinin has since been removed from the market. When normalized to patient size and levels excised, the use of TXA resulted in a reduction in intraoperative EBL.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Clot Retraction and Fibrinolysis
Local Anesthetics: Clinical Application as Intravenous Regional Anesthesia
One of the advantages of...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Local Anesthetics: Clinical Application as Spinal Anesthesia
